JP2002508373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002508373A5 JP2002508373A5 JP2000539019A JP2000539019A JP2002508373A5 JP 2002508373 A5 JP2002508373 A5 JP 2002508373A5 JP 2000539019 A JP2000539019 A JP 2000539019A JP 2000539019 A JP2000539019 A JP 2000539019A JP 2002508373 A5 JP2002508373 A5 JP 2002508373A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate according
- hydrate
- diabetes
- exhibits
- complications
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000001237 Raman spectrum Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NQLCBKFSQDRLKI-UAIGNFCESA-N O.C(\C=C/C(=O)O)(=O)O.S1C(NC(C1)=O)=O Chemical compound O.C(\C=C/C(=O)O)(=O)O.S1C(NC(C1)=O)=O NQLCBKFSQDRLKI-UAIGNFCESA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9726566.4 | 1997-12-16 | ||
| GBGB9726566.4A GB9726566D0 (en) | 1997-12-16 | 1997-12-16 | Novel pharmaceutical |
| PCT/EP1998/008155 WO1999031095A1 (en) | 1997-12-16 | 1998-12-14 | 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002508373A JP2002508373A (ja) | 2002-03-19 |
| JP2002508373A5 true JP2002508373A5 (https=) | 2006-02-09 |
Family
ID=10823692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000539019A Withdrawn JP2002508373A (ja) | 1997-12-16 | 1998-12-14 | 医薬としての５−［４−［２−（ｎ−メチル−ｎ−（２−ピリジル）アミノ）エトキシ］ベンジル］チアゾリジン−２，４−ジオン・マレイン酸塩水和物 |
Country Status (35)
| Country | Link |
|---|---|
| EP (2) | EP1040110A1 (https=) |
| JP (1) | JP2002508373A (https=) |
| KR (1) | KR100549142B1 (https=) |
| CN (3) | CN101381367A (https=) |
| AP (1) | AP1365A (https=) |
| AR (1) | AR017214A1 (https=) |
| AU (1) | AU1967999A (https=) |
| BG (1) | BG64988B1 (https=) |
| BR (1) | BR9813600A (https=) |
| CA (1) | CA2314107A1 (https=) |
| CO (1) | CO4980880A1 (https=) |
| CZ (1) | CZ299965B6 (https=) |
| DZ (1) | DZ2681A1 (https=) |
| EA (1) | EA004260B1 (https=) |
| EG (1) | EG22337A (https=) |
| GB (1) | GB9726566D0 (https=) |
| HR (1) | HRP20000408B1 (https=) |
| HU (1) | HUP0100509A3 (https=) |
| IL (1) | IL136424A (https=) |
| IN (1) | IN192487B (https=) |
| MA (1) | MA26580A1 (https=) |
| MY (1) | MY135612A (https=) |
| NO (1) | NO317254B1 (https=) |
| OA (1) | OA11766A (https=) |
| PE (1) | PE20000058A1 (https=) |
| PL (1) | PL341146A1 (https=) |
| RS (1) | RS50126B (https=) |
| SA (1) | SA99191115B1 (https=) |
| SK (1) | SK286618B6 (https=) |
| TR (2) | TR200001799T2 (https=) |
| TW (1) | TW509690B (https=) |
| UA (1) | UA72198C2 (https=) |
| UY (2) | UY25304A1 (https=) |
| WO (1) | WO1999031095A1 (https=) |
| ZA (1) | ZA9811506B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9726568D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| US6664278B2 (en) | 1997-12-16 | 2003-12-16 | Smithkline Beecham P.L.C. | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| GB9909041D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Plc | Novel pharmaceutical |
| UA67844C2 (uk) * | 1999-04-23 | 2004-07-15 | Смітклайн Бічам Плс | Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти |
| DE60004658T2 (de) * | 1999-04-23 | 2004-06-24 | Smithkline Beecham Plc, Brentford | Thiazolidindionderivat und seine verwendung als antidiabetikum |
| PL351685A1 (en) * | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Novel pharmaceutical |
| MXPA02010545A (es) | 2000-04-25 | 2004-05-14 | Kyorin Seiyaku Kk | Cristal estable novedoso de derivado de tiazolidinediona y proceso para producir el mismo. |
| GB0014005D0 (en) * | 2000-06-08 | 2000-08-02 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0021784D0 (en) * | 2000-09-05 | 2000-10-18 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0021978D0 (en) * | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
| CZ2003864A3 (cs) * | 2000-09-26 | 2004-01-14 | Dr. Reddy´S Research Foundation | Nové polymorfní formy 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidin-2,4-dion-maleátu a způsob jejich přípravy |
| UA75370C2 (en) * | 2000-09-26 | 2006-04-17 | Reddys Lab Ltd Dr | Polymorphic forms of 5-[4-[2(n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2.4-dione maleate |
| GB0129876D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0129872D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| WO2003050112A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Toluenesulfonate hydrates of a thiazolidinedione derivative |
| GB2405403A (en) * | 2003-08-29 | 2005-03-02 | Cipla Ltd | Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base |
| ITMI20041537A1 (it) * | 2004-07-28 | 2004-10-28 | Chemi Spa | Nuova forma polimorfa del rosiglitazone maleato |
| CZ298424B6 (cs) * | 2005-05-24 | 2007-09-26 | Zentiva, A. S. | Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel |
| EP2184055A1 (en) | 2008-11-07 | 2010-05-12 | LEK Pharmaceuticals d.d. | Process for preparing solid dosage forms of rosiglitazone maleate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG59988A1 (en) * | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| GB8820389D0 (en) * | 1988-08-26 | 1988-09-28 | Beecham Group Plc | Novel compounds |
| GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| MX9603338A (es) * | 1994-02-10 | 1997-03-29 | Smithkline Beecham Plc | Uso de sensibilizadores a la insulina para tratar enfermedades renales. |
-
1997
- 1997-12-16 GB GBGB9726566.4A patent/GB9726566D0/en not_active Ceased
-
1998
- 1998-12-14 UA UA2000063485A patent/UA72198C2/uk unknown
- 1998-12-14 CA CA002314107A patent/CA2314107A1/en not_active Abandoned
- 1998-12-14 IL IL13642498A patent/IL136424A/xx unknown
- 1998-12-14 SK SK917-2000A patent/SK286618B6/sk not_active IP Right Cessation
- 1998-12-14 EP EP98964510A patent/EP1040110A1/en not_active Withdrawn
- 1998-12-14 JP JP2000539019A patent/JP2002508373A/ja not_active Withdrawn
- 1998-12-14 MA MA25389A patent/MA26580A1/fr unknown
- 1998-12-14 CN CNA200810087031XA patent/CN101381367A/zh active Pending
- 1998-12-14 CN CNA2008100870305A patent/CN101302215A/zh active Pending
- 1998-12-14 HR HR20000408A patent/HRP20000408B1/xx not_active IP Right Cessation
- 1998-12-14 HU HU0100509A patent/HUP0100509A3/hu unknown
- 1998-12-14 RS YUP-363/00A patent/RS50126B/sr unknown
- 1998-12-14 EP EP05077331A patent/EP1661895A1/en not_active Withdrawn
- 1998-12-14 PL PL98341146A patent/PL341146A1/xx not_active Application Discontinuation
- 1998-12-14 WO PCT/EP1998/008155 patent/WO1999031095A1/en not_active Ceased
- 1998-12-14 CN CN98812089A patent/CN1281453A/zh active Pending
- 1998-12-14 KR KR1020007006515A patent/KR100549142B1/ko not_active Expired - Fee Related
- 1998-12-14 AP APAP/P/2000/001831A patent/AP1365A/en active
- 1998-12-14 OA OA1200000178A patent/OA11766A/en unknown
- 1998-12-14 BR BR9813600-3A patent/BR9813600A/pt not_active Application Discontinuation
- 1998-12-14 TR TR2000/01799T patent/TR200001799T2/xx unknown
- 1998-12-14 EA EA200000654A patent/EA004260B1/ru not_active IP Right Cessation
- 1998-12-14 AU AU19679/99A patent/AU1967999A/en not_active Abandoned
- 1998-12-14 CZ CZ20002204A patent/CZ299965B6/cs not_active IP Right Cessation
- 1998-12-15 UY UY25304A patent/UY25304A1/es unknown
- 1998-12-15 MY MYPI98005674A patent/MY135612A/en unknown
- 1998-12-15 UY UY25308A patent/UY25308A1/es not_active IP Right Cessation
- 1998-12-15 AR ARP980106370A patent/AR017214A1/es unknown
- 1998-12-15 EG EG155698A patent/EG22337A/xx active
- 1998-12-15 DZ DZ980291A patent/DZ2681A1/xx active
- 1998-12-15 ZA ZA9811506A patent/ZA9811506B/xx unknown
- 1998-12-16 CO CO98074834A patent/CO4980880A1/es unknown
- 1998-12-16 TR TR1998/02625A patent/TR199802625A3/tr unknown
- 1998-12-16 TW TW087121121A patent/TW509690B/zh not_active IP Right Cessation
- 1998-12-16 IN IN3772DE1998 patent/IN192487B/en unknown
- 1998-12-16 PE PE1998001233A patent/PE20000058A1/es not_active Application Discontinuation
-
1999
- 1999-02-27 SA SA99191115A patent/SA99191115B1/ar unknown
-
2000
- 2000-06-15 NO NO20003069A patent/NO317254B1/no not_active IP Right Cessation
- 2000-07-13 BG BG104603A patent/BG64988B1/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002508371A5 (https=) | ||
| JP2002508373A5 (https=) | ||
| TWI322686B (en) | Compound and pharmaceutical composition for large conductance calcium-activated k channel opener | |
| JP2002508372A5 (https=) | ||
| JP5269758B2 (ja) | 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体 | |
| TW487709B (en) | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, its preparation and its use | |
| JP2002535401A5 (https=) | ||
| JP5149271B2 (ja) | 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体 | |
| JP2002519425A5 (https=) | ||
| JP2005539053A5 (https=) | ||
| WO2005077368A2 (en) | Treatment of gastro-esophageal reflux disease (gerd) | |
| JP2004535466A5 (https=) | ||
| JP2005517006A5 (https=) | ||
| JP2003516310A (ja) | 新規治療方法 | |
| JP2008534453A5 (https=) | ||
| JP2005526696A5 (https=) | ||
| EA200101121A1 (ru) | Полиморф 5-[4-[2-(n-метил-n-(2-пиридил) амино) этокси] бензил] тиазолидин-2,4-диона, соли малеиновой кислоты | |
| TW509690B (en) | Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt, its preparation and its use | |
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| EA200101119A1 (ru) | Новый фармацевтический препарат | |
| US20070032501A1 (en) | Aryl pyridines and methods of their use | |
| CA2554616A1 (en) | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist | |
| CA2202484C (en) | Use of indole derivatives for the treatment of various diseases | |
| NZ513922A (en) | Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione | |
| JP2005516035A5 (https=) |